All News

Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/CG9ClLHEW6 https://t.co/DPekHWjTsP

Links:

https://bit.ly/44iT6KR

Dr. John Cush RheumNow ( View Tweet)

Jun 27, 2023

With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW

Bella Mehta bella_mehta ( View Tweet)

Jun 03, 2023

#EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few years @RheumNow https://t.co/Oh8sZlMzUt

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Jun 02, 2023

JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Jun 01, 2023

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0

Dr. John Cush RheumNow ( View Tweet)

Jun 01, 2023

Professor Ingrid Lundberg reviews the co associations amongst the inflammatory myopathies #EULAR2023 https://t.co/B9Idyz90Lh

Dr. John Cush RheumNow ( View Tweet)

Jun 01, 2023

Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG). https://t.co/tYOwsNaiGy https://t.co/Bpfft4J9MB

Links:

https://bit.ly/42OIDWY

Dr. John Cush RheumNow ( View Tweet)

May 15, 2023

Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis

Save

d Jack Cush, MD

May 11, 2023

A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).

Read Article

The Match Game (4.14.2023)

Save

d Jack Cush, MD

Apr 14, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.

Read Article

Japanese cohort study shows Lung cancer is more common in males w/ elder-onset dermatomyositis - risk increased by Smoking, anti-TIF1-γ-Abs and elevated MLR (monocyte to lymphocyte ratio) https://t.co/LlTkiWp7pb https://t.co/Bu9atnI8je

Links:

https://bit.ly/3mC08Kl

Dr. John Cush RheumNow ( View Tweet)

Apr 13, 2023

NEJM Clinical image: 61-year-old woman presented with a 6-month history of periorbital swelling and shoulder weakness. The physical examination was notable for erythema of the upper and lower eyelids and substantial periorbital edema. Dermatomyositis. https://t.co/1Vu1Lh37Hd https://t.co/Bh7FXDgMRx

Links:

https://bit.ly/3ZVefIn

Dr. John Cush RheumNow ( View Tweet)

Apr 11, 2023

Ccancer detection study in idiopathic inflammatory myositis: found w/in 3 yrs of onset 9/1011 (0.9%) CT chest & 12/657(1.8%) CT Dx cancer. Yield best w/ DM, TIF1γ pos. Yield very low age<40 yrs; high false(+) w/ antisynthetase synd & necrotizing myositis https://t.co/FCBwEYW1eT https://t.co/DAEj83xmam

Links:

https://bit.ly/3YRS6do

Dr. John Cush RheumNow ( View Tweet)

Mar 15, 2023

Big Time Vasculitis (3.10.2023)

Save

d Jack Cush, MD

Mar 10, 2023

Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?

Read Article

Long-Term Survival of Idiopathic Inflammatory Myopathies

Save

d Jack Cush, MD

Mar 09, 2023

A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.

Read Article

Drs Schett & Mackensen reported a case of refractory inflammatory myositis successfully treated with CD19 CAR T cells. 41yoM w/ +Jo-1, myositis, ILD, Raynauds, periorb edema, not responding to steroids, RTX, IVIG, tacrolimus, CTX https://t.co/DlKs3DGWNu https://t.co/M7qrcfcE2y

Links:

https://bit.ly/3kNUOTe

Dr. John Cush RheumNow ( View Tweet)

Mar 06, 2023

NSAIDs in Pregnancy (3.3.2023)

Save

d Jack Cush, MD

Mar 03, 2023

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Read Article

Differential Dx of Granulomatous Myopathy: Sarcoidosis, inclusion-body myositis, myasthenia gravis, Crohns, GPA, TB, brucellosis, syphilis, PBC, RA, systemic sclerosis , lymphoma, checkpoint inhibitors, GVHD, natural killer/T-cell lymphoma https://t.co/5IUaC1ln7G https://t.co/guYtvyaaHU

Links:

https://bit.ly/3kcmMrz

Dr. John Cush RheumNow ( View Tweet)

Feb 20, 2023

Burnout #10 (2.3.2023)

Save

d Jack Cush, MD

Feb 03, 2023

Dr. Jack Cush reviews the past week of news on RheumNow.com.

Read Article

US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). Downward trend in DM/PM mortality (<7%); plus PM/DM was 2X more likely to be one of mult causes, instead of, sole cause of death. https://t.co/9KZKr8JxUE https://t.co/7acK0eHVku

Links:

https://bit.ly/3l2i53P

Dr. John Cush RheumNow ( View Tweet)

Feb 01, 2023

Simon Says “Don’t Do This” (1.27.2022)

Save

d Jack Cush, MD

Jan 27, 2023

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.

Read Article

Topics

All News